Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026[1], as part of Board...
Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and...
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology...
SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small...